1-3 of 3
Stefan Hantel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes

Petter Bjornstad, Lori Laffel, William V. Tamborlane, Gudrun Simons, Stefan Hantel, Maximilian von Eynatten, Jyothis George, Jan Marquard, David Z.I. Cherney
Journal: Diabetes Care
Diabetes Care 2018;41(8):e129–e130
DOI: https://doi.org/10.2337/dc18-0394
Published: 25 June 2018
View article titled, Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes
Click here to open pdf in another window PDF for Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes
Journal Articles

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

Silvio E. Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T. George, Stefan Hantel, Erich Bluhmki, John M. Lachin
Journal: Diabetes Care
Diabetes Care 2018;41(2):356–363
DOI: https://doi.org/10.2337/dc17-1096
Published: 04 December 2017
View article titled, How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Click here to open pdf in another window PDF for How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Includes: Supplementary data
Journal Articles

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

Ele Ferrannini, MD, Andreas Berk, PHD, Stefan Hantel, PHD, Sabine Pinnetti, MD, Thomas Hach, MD, Hans J. Woerle, MD, Uli C. Broedl, MD
Journal: Diabetes Care
Diabetes Care 2013;36(12):4015–4021
DOI: https://doi.org/10.2337/dc13-0663
Published: 13 November 2013
View article titled, Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: <span class="subtitle">An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes</span>
Click here to open pdf in another window PDF for Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: <span class="subtitle">An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes</span>
Includes: Supplementary data